Replies to post #38865 on RespireRx Pharmaceuticals Inc (RSPI)

[Market_Fest4]

That 24 year old died yesterday from profenol. It would seem that somebody would want ampakines just to test for counteracting opioid narcotic effect?

But nobody even appears to know or care about cortex.
MF4

[enemem]

opioid-induced deaths continue to rise:

http://www.ama-assn.org/ams/pub/amawire/2013-february-27/2013-february-27-physician.shtml

The bag-holders have to decide whether they are happy with pennies on the dollar, or whether they want to bring a low-impact forward to target opioid-induced RD. Efficacy has been established, and this could be a block-buster. It is a more focused drug development program than Varney's ill-fated and foolish SA gambit.

If it is accurate that Varney looked high and low and couldn't find a buyer, it's not clear to me that this new group is going to have any more success. Yes, Varney may have disregarded low-ball offers, but it isn't clear that these low-ball offers are any more attractive to the people running things now.